Analyzing Imprimis Pharmaceuticals (IMMY) & Ardelyx (ARDX)
Imprimis Pharmaceuticals (NASDAQ: IMMY) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.
Insider and Institutional Ownership
12.6% of Imprimis Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.9% of Ardelyx shares are owned by institutional investors. 12.6% of Imprimis Pharmaceuticals shares are owned by insiders. Comparatively, 15.5% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and target prices for Imprimis Pharmaceuticals and Ardelyx, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Imprimis Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 179.33%. Ardelyx has a consensus target price of $13.67, indicating a potential upside of 113.54%. Given Imprimis Pharmaceuticals’ higher possible upside, equities analysts clearly believe Imprimis Pharmaceuticals is more favorable than Ardelyx.
This table compares Imprimis Pharmaceuticals and Ardelyx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Imprimis Pharmaceuticals has a beta of -0.27, indicating that its share price is 127% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500.
Valuation and Earnings
This table compares Imprimis Pharmaceuticals and Ardelyx’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Imprimis Pharmaceuticals||$19.94 million||1.84||-$19.08 million||($0.92)||-1.95|
|Ardelyx||$24.03 million||12.66||-$112.38 million||($2.23)||-2.87|
Imprimis Pharmaceuticals has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Imprimis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Ardelyx beats Imprimis Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.
Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company’s cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.
Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.